892 results about "Control release" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are implantable intraocular drug delivery devices structured to provide targeted and / or controlled release of a drug to a desired intraocular target tissue, and methods of implanting and methods of using such devices for the treatment of ocular diseases and disorders. In certain embodiments, some, most, or essentially all of the device is made of biodegradable materials.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

The invention discloses a buccal nicotine bag product and a preparation method thereof. The buccal nicotine bag product comprises a content and an outer package, the content is powdery and comprises a nicotine source and an acidic pH regulator; the outer package is a saliva permeable pouch and is used for packaging the content, so that the pH value of the buccal nicotine pouch product in pure water or saliva is smaller than 6.0. Optimizing the pH value to a weakly acidic range (pH lt; a specific buffer system and a slow-release carrier are combined to solve the problems of oral cavity stimulation, flavor limitation and high pH dependence in the using process of an existing nicotine bag, the palatability of the nicotine bag in the using process and the nicotine release efficiency in the mouth consumption process are improved, long-acting and stable nicotine delivery is achieved by controlling release kinetics, the production cost is reduced, and the nicotine bag is suitable for large-scale popularization and application. The consumption experience is improved.

The invention discloses functional injection type bionic hydrogel for promoting bone healing and a preparation method thereof, and relates to the technical field of medical instruments. The hydrogel has good functional characteristics, is a biomimetic material prepared on the basis of methacrylated gelatin, and aims to regulate and control the degradation rate, the drug release mechanism and diversified synergistic treatment and promote bone repair and regeneration; according to the hydrogel, matching of the degradation rate and the bone regeneration rate is achieved through reasonable matching, stem cell osteogenic differentiation and angiogenesis are promoted, ultrasonic controlled-release drug release and synergistic controlled-release of active factors are achieved, inflammation is reduced, and the bone repair process is promoted; the calcium phosphate bone cement provides biocompatibility and bone conductivity, and the nano clay releases active ions to improve the microenvironment and promote bone repair; in addition, the magnetic nanoparticles and a static magnetic field have synergistic interaction, the bone healing process is further accelerated, and treatment effect monitoring is enhanced through magnetic resonance imaging.

The invention relates to the technical field of medicines, and discloses a mannose / trimethyl chitosan modified MXene material (MTC / MXene), a preparation method and application of the mannose / trimethyl chitosan modified MXene material in prevention and treatment of inflammatory bowel diseases. The MTC / MXene material is obtained by preparing mannose-modified trimethyl chitosan and modifying the mannose-modified trimethyl chitosan on a single-layer MXene nanosheet, compared with a pure MXene material, MTC modification endows MXene with hydrophilicity, rich reaction sites are provided for drug loading, higher oxidation resistance is achieved, meanwhile, through surface functional groups and interlayer gaps of the MXene material, the MXene / MTC / MXene material can be used for preparing the drug, and the drug loading efficiency is improved. Different types of drug molecules are loaded and are used for realizing targeted delivery and controlled release of drugs.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The microcapsule controlled-release efficient deodorization paper diaper comprises a deodorization surface layer, a flow guide layer, a composite core body and a bottom layer which are sequentially compounded, the deodorization surface layer is coated with deodorization antibacterial liquid containing controlled-release microcapsules, the composite core body is composed of a rapid absorption layer and a deodorization water locking layer, the rapid absorption layer and the deodorization water locking layer both contain controlled-release microcapsules, and the bottom layer is coated with deodorization antibacterial liquid containing controlled-release microcapsules. The preparation method comprises the following steps: S1, preparing quaternary ammonium salt chitosan; s2, preparing an inner core layer of the controlled-release microcapsule; the preparation method comprises the following steps: S1, preparing a shell layer, S2, preparing quaternary ammonium salt chitosan, S3, preparing amphiphilic chitosan microspheres, S4, loading a natural plant extract on the amphiphilic chitosan microspheres, S5, coating the shell layer to prepare a controlled-release microcapsule, S6, preparing a deodorization surface layer, S7, preparing a composite core body, and S8, carrying out composite molding on the paper diaper. The deodorization efficiency and durability are obviously improved, and meanwhile, the paper diaper is kept dry and comfortable.

The invention discloses functional factor-loaded bi-crosslinked food gel and a preparation method thereof, and belongs to the technical field of food processing. The preparation method comprises the following steps: by taking protein, edible oil and fat, kappa-carrageenan, gellan gum and the like as main gel base materials, firstly, inducing by adopting potassium ions to form protein-kappa-carrageenan or protein-gellan gum composite gel; and dipping the composite gel in an acid solution, and inducing to form the bi-crosslinked protein-kappa-carrageenan or protein-gellan gum composite gel. The method can be used for preparing protein-kappa-carrageenan or protein-gellan gum composite hydrogel and composite emulsion gel, can be used for preparing double-crosslinking gel at lower protein and polysaccharide concentration, and can obviously improve the hardness of the gel, reduce the swelling rate of the gel and improve the stability of the gel. The prepared double-crosslinking composite gel can realize co-embedding of hydrophilic and hydrophobic functional factors, and the stability and the controlled release characteristic of the functional factors are remarkably improved.

Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The embodiment of the invention provides breast cancer targeting nanoparticles as well as a preparation method and application thereof. According to the embodiment of the invention, the breast cancer targeting nanoparticles are synthesized by preparing the pH sensitive polymer, carrying out co-coupling modification on the pH response polymer and the folic acid albumin nano-carrier and utilizing a controlled desolvation method; the breast cancer targeting nanoparticle is combined with a nano preparation passive targeting strategy, a tumor microenvironment stimulation response strategy and a folic acid active targeting strategy, the effects of an EPR effect, PEG shedding, charge overturning, folic acid ligand-receptor combination and the like are utilized, precise targeting and specific response of tumors are achieved, and targeted accumulation of drugs in a tumor microenvironment is comprehensively improved. Therefore, the breast cancer targeting nanoparticles prepared by the embodiment have the advantages of high targeting property, drug controlled release, improvement of solubility and absorptivity of indissolvable drugs and the like, so that the curative effect of the drugs can be enhanced, the toxic and side effects can be reduced, and the breast cancer targeting nanoparticles have wide application prospects in the field of anti-tumor treatment.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention particularly relates to a curcumin delivery system based on small extracellular vesicles, a preparation method and application. Curcumin has the defects of poor water solubility, poor chemical stability and insufficient targeting, in order to improve the bioavailability of curcumin, the curcumin delivery system based on small extracellular vesicles provided by the invention adopts RGD peptide surface modified sEVs as a carrier to coat curcumin, and saponin is used for assisting ultrasonic drug loading, so that the drug loading rate of curcumin is improved. According to verification of the invention, the delivery system can effectively improve the in-vitro release performance of the curcumin preparation and realize controlled release and slow release. Meanwhile, the delivery system effectively improves apoptosis induction of curcumin to glioma cells, the blood-brain barrier penetrating capacity of the curcumin delivery system is improved, and the treatment effect on brain glioma is expected to be improved.

The invention belongs to the technical field of biological medicines, and particularly relates to sodium pyruvate sustained-release gel nanoparticles based on redox response as well as a preparation method and application of the sodium pyruvate sustained-release gel nanoparticles. The preparation method comprises the following steps: adding modified gellan gum containing sulfydryl and catechol groups, phenylboronic acid modified gellan gum and sodium pyruvate into water to obtain a mixed solution; under the protection of inert gas, divalent metal salt and potassium persulfate are added into the mixed solution, stirring is performed for 3-5 h, after the reaction is finished, centrifugation is performed, precipitates are collected, washed and dried, and the composite material is obtained. Experimental results show that the sodium pyruvate sustained-release gel nanoparticles prepared by the invention can realize controlled release of drugs, reduce toxic and side effects caused by burst release of the drugs, improve the curative effect of the drugs and improve the bioavailability.

Non-aqueous membrane emulsion methods for producing polymeric and polymer-coated microparticles are provided. Some embodiments provide methods for producing a sustained release or controlled release microparticle by combining micronized protein powder and a polymer into a hydrocarbon solvent to form a non-aqueous first solution, agitating the first non-aqueous solution to form a suspension, feeding the suspension into a dispersion pump, wherein the suspension is infused through a porous membrane into a continuous phase comprising a fluorocarbon liquid and a fluorosurfactant to form a hydrocarbon-in-fluorocarbon emulsion. The hydrocarbon solvent, the fluorocarbon liquid, and the fluorosurfactant are removed, and the microparticles are collected.

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.

The invention belongs to the technical field of biological materials, and particularly relates to nano composite hydrogel as well as a preparation method and application thereof. In the preparation process of the hydrogel, preparation of gelatin hydrazide and preparation of pullulan oxidation are sequentially completed, then preparation of active component loaded PLGA nanoparticles and self-assembly coating with metal-polyphenol are completed, and finally, the metal-polyphenol coated PLGA nanoparticles are mixed with gelatin hydrazide and pullulan oxidation to form gel in situ. The hydrogel has the characteristics of injectability, self-healing, wet adhesion and the like, the metal-polyphenol layer has the effects of resisting inflammation, resisting oxidation and promoting angiogenesis and generates photo-thermal response to near infrared rays, on-demand controllable release of the drug-loaded nanoparticles is achieved, the composite hydrogel can improve the wound surface microenvironment, promote angiogenesis and inhibit inflammation and scar formation, and the drug-loaded nanoparticles can be applied to wound healing. The ointment is suitable for burns, scalds and various complex wounds.